ATE495197T1 - Chimäre konstrukte zwischen auf krebs zielenden peptiden und zellpenetrierenden peptiden gekoppelt an antikrebsmittel und/oder diagnostische mittel - Google Patents

Chimäre konstrukte zwischen auf krebs zielenden peptiden und zellpenetrierenden peptiden gekoppelt an antikrebsmittel und/oder diagnostische mittel

Info

Publication number
ATE495197T1
ATE495197T1 AT07716076T AT07716076T ATE495197T1 AT E495197 T1 ATE495197 T1 AT E495197T1 AT 07716076 T AT07716076 T AT 07716076T AT 07716076 T AT07716076 T AT 07716076T AT E495197 T1 ATE495197 T1 AT E495197T1
Authority
AT
Austria
Prior art keywords
cell
seq
peptides
cancer
targing
Prior art date
Application number
AT07716076T
Other languages
English (en)
Inventor
Uelo Langel
Helena Myrberg
Maarja Maee
Erkki Ruoslahti
Lianglin Zhang
Original Assignee
Cepep Iii Ab
Burnham Inst Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cepep Iii Ab, Burnham Inst Medical Research filed Critical Cepep Iii Ab
Application granted granted Critical
Publication of ATE495197T1 publication Critical patent/ATE495197T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT07716076T 2006-03-20 2007-03-20 Chimäre konstrukte zwischen auf krebs zielenden peptiden und zellpenetrierenden peptiden gekoppelt an antikrebsmittel und/oder diagnostische mittel ATE495197T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78339606P 2006-03-20 2006-03-20
PCT/SE2007/000268 WO2007108749A1 (en) 2006-03-20 2007-03-20 Chimeric constructs between cancer-homing peptides and cell-penetrating peptides coupled to anticancer drugs and/or diagnostic agent/agents

Publications (1)

Publication Number Publication Date
ATE495197T1 true ATE495197T1 (de) 2011-01-15

Family

ID=38522712

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07716076T ATE495197T1 (de) 2006-03-20 2007-03-20 Chimäre konstrukte zwischen auf krebs zielenden peptiden und zellpenetrierenden peptiden gekoppelt an antikrebsmittel und/oder diagnostische mittel

Country Status (5)

Country Link
US (1) US20100279918A1 (de)
EP (1) EP1991586B1 (de)
AT (1) ATE495197T1 (de)
DE (1) DE602007011901D1 (de)
WO (1) WO2007108749A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514839A (ja) 2007-01-03 2010-05-06 バーナム インスティテュート フォー メディカル リサーチ クロット結合化合物に関連する方法および組成物
JP2011514160A (ja) * 2008-02-21 2011-05-06 バーナム インスティテュート フォー メディカル リサーチ Ｃ末端エレメントを有するペプチドおよびタンパク質に関する方法および組成物
WO2011005540A1 (en) 2009-06-22 2011-01-13 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
WO2011020107A2 (en) * 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
CA2784145A1 (en) 2009-12-18 2011-06-23 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
CA2800730C (en) * 2010-05-30 2019-06-11 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for antimicrobials
CN103097397B (zh) * 2010-05-30 2015-11-25 多伦多大学管理委员会 作为抗癌化合物载体的线粒体穿透肽
EP2671597A1 (de) * 2012-06-07 2013-12-11 Cepep III AB Chimäre Konstrukte zwischen gliomabzielendem Peptid und zellpenetrierenden Peptiden, gHoPe2
AU2013302861A1 (en) 2012-08-13 2015-03-05 The Rockefeller University Treatment and diagnosis of melanoma
CN103981147B (zh) 2013-02-08 2017-11-10 中国科学院上海生命科学研究院 一种新的制备肝实质细胞的方法
WO2014147193A1 (en) * 2013-03-20 2014-09-25 Centre National De La Recherche Scientifique (Cnrs) New cell-penetrating peptide motifs
JP6807831B2 (ja) * 2014-05-21 2021-01-06 エントラーダ セラピューティクス，インコーポレイテッド 細胞膜透過性ペプチド、並びにこの作製方法及び使用方法
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
WO2016033368A1 (en) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
WO2016172515A1 (en) 2015-04-23 2016-10-27 Sanford Burnham Prebys Medical Discovery Institute Targeted delivery system and methods of use therefor
US12410143B2 (en) 2017-01-17 2025-09-09 Michael David FORREST Therapeutic inhibitors of the reverse mode of ATP synthase
WO2018227112A1 (en) 2017-06-09 2018-12-13 The Trustees Of Columbia University In The City Of New York Short tat oligomers for drug delivery
BR112019028172A2 (pt) 2017-07-13 2020-10-06 Michael David Forrest moduladores terapêuticos do modo reverso da atp sintase
CA3078504A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
CA3078981A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
WO2019148195A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of cal-pdz binding domain
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
US11987647B2 (en) 2018-05-09 2024-05-21 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
CN112386707B (zh) * 2019-08-19 2023-08-11 辽宁医学诊疗科技研发中心有限公司 一种肿瘤靶向多肽药物偶联物及其制备方法
TWI888447B (zh) 2019-12-13 2025-07-01 美商因思博納公司 金屬鹽及其用途
MX2023007788A (es) 2021-01-24 2023-11-17 Michael David Forrest Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos.
EP4634373A1 (de) 2022-12-16 2025-10-22 University of Rochester Reparatur von dysfunktion der barriere in der speiseröhre

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
US7488792B2 (en) * 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
WO2004106370A1 (en) * 2003-05-28 2004-12-09 Theraptosis Sa M11l derived peptides and therapeutic use thereof
US20060182736A1 (en) * 2003-06-10 2006-08-17 Kim Jin-Soo Transducible dna-binding proteins
AU2006325030B2 (en) * 2005-12-16 2012-07-26 Cellectis Cell penetrating peptide conjugates for delivering nucleic acids into cells

Also Published As

Publication number Publication date
US20100279918A1 (en) 2010-11-04
WO2007108749A1 (en) 2007-09-27
EP1991586B1 (de) 2011-01-12
DE602007011901D1 (de) 2011-02-24
EP1991586A1 (de) 2008-11-19
WO2007108749A8 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
ATE495197T1 (de) Chimäre konstrukte zwischen auf krebs zielenden peptiden und zellpenetrierenden peptiden gekoppelt an antikrebsmittel und/oder diagnostische mittel
Ciulla et al. Structure–activity relationships of antibacterial peptides
SG10201909675QA (en) Peptide vaccines for cancers expressing tumor-associated antigens
Gentilucci et al. Peptides and peptidomimetics in medicine, surgery and biotechnology
ES2850726T3 (es) Péptidos de penetración celular para suministro intracelular de moléculas
ES2882634T3 (es) Compuestos peptídicos y conjugados con péptidos para el tratamiento del cáncer mediante quimioterapia mediada por receptores
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
EP2476697A3 (de) Peptidvakzinen für MPHOSPH1- oder DEPDC1-Polypeptide exprimierenden Krebs
EP2810661A3 (de) Disulfidvernetzte Polyethylenglycol-/Peptidkonjugate zur Transfektion von Nucleinsäuren
NZ599791A (en) Therapeutic peptides
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
Yamaguchi et al. Identification of cyclic peptides for facilitation of transcellular transport of phages across intestinal epithelium in vitro and in vivo
AR067627A1 (es) Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion
US20150119340A1 (en) Fusion peptide and use thereof for cell membrane penetrating
KR20240113714A (ko) 신규한 알파나선형 양면성 세포 투과 펩타이드 및 이의 용도
Suk Choi et al. Cell penetrating peptides for tumor targeting
MX365599B (es) Moleculas de transporte especificas de proteoglicano c4s.
AR065688A1 (es) Conjugados de peptidos antifusogenicos
Biswas et al. Applications of Peptide in Cancer Therapy
US20240092846A1 (en) Engineered cyclotides with potent broad antimicrobial activity
EP3219720A3 (de) Wdrpuh-epitop-peptide und impfstoffe damit
KR101557101B1 (ko) 미토콘드리아 타겟팅 시퀀스와 양이온성 올리고펩타이드를 유효성분으로 함유하는 미토콘드리아 약물전달용 담체
Moreno et al. Cyclic-Linear Hybrid Peptides as Molecular Transporters of Chemotherapeutic Agents
JP2018165253A (ja) 血液脳関門を透過する薬物輸送体、ペプチド及びその用途

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties